// App-Quantinova.ai

534 : A phase I trial of the IGF-1R antibody IMC-A12 in combination with temsirolimus in patients with metastatic breast cancer.

Researchers

Presenter

  • Gini F. Fleming

Principal Investigators

  • Vera Jean Suman

  • Matthew P. Goetz

  • Matthew James Ellis

  • Cynthia X. Ma

  • Paul Haluska

  • Timothy Jerome Moynihan

  • Rita Nanda

  • Olufunmilayo I. Olopade

  • Timothy J. Pluard

  • Charles Erlichman

  • Helen X. Chen

  • Zhanfang Guo

Medical Centers

  • Department of Internal Medicine, Division of Oncology and Siteman Cancer Center, Washington University Medical Center, St. Louis, MO

  • Washington University School of Medicine, St. Louis, MO

  • The University of Chicago Medical Center, Chicago, IL

  • The University of Chicago Medical Center, Chicago, IL

  • National Cancer Institute, Bethesda, MD

  • Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • C-peptide

  • Insulin-like growth factor 1 receptor

Drug/Treatment

  • Temsirolimus

  • Cixutumumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved